Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage

NANot yet recruitingINTERVENTIONAL
Enrollment

768

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Intracerebral HaemorrhageMinimally Invasive Treatment
Interventions
PROCEDURE

Stereotactic thrombolysis with Tenecteplase

Stereotactic thrombolysis with Tenecteplase for ICH is a minimally invasive method for evacuation hematoma. The hematoma puncture target is identified via CT imaging before surgery. After local anesthesia and sedation, stereotactic minimally invasive surgery is performed with the Leksell stereotactic frame. A postoperative CT scan is immediately conducted to confirm the absence of intracranial rebleeding before administering tenecteplase into the hematoma. Tenecteplase is fully diluted in 2 mL of saline and injected into the hematoma cavity via an irrigation catheter. The drainage tube is clamped for 1 hour before opening (early opening is permitted if necessary). The single dose of TNK is 0.5 mg and can be administered with a maximum of 2 dose in every 24 hours. The target hematoma clearance criteria is: residual hematoma volume ≤10 mL or ≤20% of the initial volume.

All Listed Sponsors
lead

Tongji Hospital

OTHER

NCT07208097 - Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage | Biotech Hunter | Biotech Hunter